Stocktoria
Werewolf Therapeutics, Inc. HOWL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-04-30
Werewolf Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $44.8M | $56.4M | $41.8M | $53.8M | $35.3M |
| Operating income | -$60.7M | -$73.6M | -$40.5M | -$56.1M | -$50.1M |
| Interest expense | — | — | $3.1M | $0 | — |
| Income tax | $0 | — | — | — | — |
| Net income | -$60.8M | -$70.5M | -$37.4M | -$53.8M | -$50.0M |
| EPS (diluted) | $-1.33 | $-1.63 | $-1.05 | $-1.86 | $-10.94 |
| Operating cash flow | -$60.3M | -$56.2M | -$32.6M | -$40.6M | -$42.9M |
| Free cash flow | -$60.3M | -$56.4M | -$33.4M | -$44.2M | -$43.4M |
| Cash & equivalents | $57.0M | $111.0M | $134.3M | $129.3M | $157.5M |
| Total assets | $69.4M | $126.9M | $174.8M | $160.2M | $179.2M |
| Total liabilities | $44.6M | $53.5M | $63.5M | $37.9M | $26.5M |
| Shareholders' equity | $24.8M | $73.4M | $111.4M | $122.3M | $152.8M |
Source: SEC EDGAR filings · CIK 0001785530 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.